PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING OF CREATININE-DRUG INTERACTION IN CHRONIC KIDNEY DISEASE POPULATION.

被引：0
|
作者：
Takita, H. [1 ,2 ]
Scotcher, D. [1 ]
Chinnadurai, R. [3 ]
Kalra, P. [3 ]
Galetin, A. [1 ]
机构：
[1] Univ Manchester, Manchester, Lancs, England
[2] Asahi Kasei Pharma, Shizuoka, Japan
[3] Salford Royal NHS Fdn Trust, Salford, Lancs, England
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2020年 / 107卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PIII-130
引用
收藏
页码：S113 / S114
页数：2
相关论文
共 50 条
  • [41] Evaluating the impact of co-administered drug and disease on ripretinib exposure: A physiologically-based pharmacokinetic modeling approach
    Pan, Chunyang
    Cheng, Yifan
    He, Qingfen
    Li, Min
    Bu, Fengjiao
    Zhu, Xiao
    Li, Xiaoyu
    Xiang, Xiaoqiang
    [J]. CHEMICO-BIOLOGICAL INTERACTIONS, 2023, 373
  • [42] Evaluation of the drug-drug interaction potential of treosulfan using a physiologically-based pharmacokinetic modelling approach
    Schaller, Stephan
    Martins, Frederico S.
    Balazki, Pavel
    Bohm, Sonja
    Baumgart, Joachim
    Hilger, Ralf A.
    Beelen, Dietrich W.
    Hemmelmann, Claudia
    Ring, Arne
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (04) : 1722 - 1734
  • [43] Physiologically-based pharmacokinetic modeling predicts the drug interaction potential of GLS4 in co-administered with ritonavir
    Sun, Zexu
    Zhao, Nan
    Xie, Ran
    Jia, Bo
    Xu, Junyu
    Luo, Lin
    Zhuang, Yulei
    Peng, Yuyu
    Liu, Xinchang
    Zhang, Yingjun
    Zhao, Xia
    Liu, Zhaoqian
    Cui, Yimin
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024,
  • [44] Modeling the complexity of drug-drug interactions: A physiologically-based pharmacokinetic study of Lenvatinib with Schisantherin A/Schisandrin A
    Zheng, Aole
    Yang, Dongsheng
    Pan, Chunyang
    He, Qingfeng
    Zhu, Xiao
    Xiang, Xiaoqiang
    Ji, Peiying
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 196
  • [45] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING (PBPK) OF PITAVASTATIN AND ATORVASTATIN TO PREDICT DRUG-DRUG INTERACTIONS (DDIS).
    Duan, P.
    Zhao, P.
    Zhang, L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S16 - S17
  • [46] Prediction of drug–drug interaction potential using physiologically based pharmacokinetic modeling
    Jee Sun Min
    Soo Kyung Bae
    [J]. Archives of Pharmacal Research, 2017, 40 : 1356 - 1379
  • [47] Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug Labeling
    Samant, Tanay S.
    Huth, Felix
    Umehara, Kenichi
    Schiller, Hilmar
    Dhuria, Shyeilla, V
    Elmeliegy, Mohamed
    Miller, Michelle
    Chakraborty, Abhijit
    Heimbach, Tycho
    He, Handan
    Ji, Yan
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (03) : 575 - 585
  • [48] Physiologically-based pharmacokinetic modeling of prominent oral contraceptive agents and applications in drug-drug interactions
    Lewis, Gareth J.
    Ahire, Deepak
    Taskar, Kunal S.
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (04): : 563 - 575
  • [49] Application of physiologically-based pharmacokinetic modeling in hepatic impairment populations
    Sager, Jennifer
    Hsu, Matt
    Isoherranen, Nina
    Wienkers, Larry
    Wahlstrom, Jan
    Foti, Robert
    [J]. FASEB JOURNAL, 2014, 28 (01):
  • [50] Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion
    K. Sandy Pang
    Matthew R. Durk
    [J]. Journal of Pharmacokinetics and Pharmacodynamics, 2010, 37 : 591 - 615
12345